Research reportCholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats

- We studied the impact of cholinergic antagonist on learning and memory in rats.
- Several doses of 3-quinuclidinyl benzilate (QNB) were tested using water maze and passive avoidance.
- QNB affected specifically stage of acquisition.
- Use as a pharmacological model of Alzheimer disease is proposed.

3-Quinuclidinyl benzilate (QNB) represents a non-selective, competitive antagonist of cholinergic receptors, which has been previously used to generate cognitive deficits in animal models of neurodegenerative disorders. The aim of this study was evaluation of QNB potency for creation of cognitive impairment during the acquisition, consolidation and retrieval stages of learning and memory in rats.Male Wistar rats were subjected to a water maze task with hidden platform and a step-through passive avoidance task. The water maze test was carried out in two separate experiments focused on spatial learning (acquisition test) and long-term spatial memory (retrieval test). QNB doses (0.5, 1.0, 2.0 and 5.0 mg kg−1) were administered to rats intraperitoneally before training sessions (acquisition test) or before probe trial (retrieval test). A QNB dose of 2.0 mg kg−1 was administered to rats in the passive avoidance task before training (acquisition test), immediately post-training (consolidation test) or 24 h pre-retention (retrieval test).QNB significantly impaired the acquisition in the water maze at doses 0.5-5.0 mg kg−1 as well as the acquisition of passive avoidance task. In contrast, consolidation and retrieval were not affected by QNB, indicating that QNB specifically affects the stage of acquisition.